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Abstract
Background: Minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) are glomerular
diseases characterized by nephrotic syndrome. Their diagnosis requires a renal biopsy, but it is an invasive
procedure with potential complications. In a small biopsy sample, where only normal glomeruli are observed, FSGS
cannot be differentiated from MCD. The correct diagnosis is crucial to an effective treatment, as MCD is normally
responsive to steroid therapy, whereas FSGS is usually resistant.
The purpose of our study was to discover and validate novel early urinary biomarkers capable to differentiate
between MCD and FSGS.
Methods: Forty-nine patients biopsy-diagnosed of MCD and primary FSGS were randomly subdivided into a
training set (10 MCD, 11 FSGS) and a validation set (14 MCD, 14 FSGS). The urinary proteome of the training set was
analyzed by two-dimensional differential gel electrophoresis coupled with mass spectrometry. The proteins
identified were quantified by enzyme-linked immunosorbent assay in urine samples from the validation set.
Results: Urinary concentration of alpha-1 antitrypsin, transferrin, histatin-3 and 39S ribosomal protein L17 was
decreased and calretinin was increased in FSGS compared to MCD. These proteins were used to build a decision
tree capable to predict patient’s pathology.
Conclusions: This preliminary study suggests a group of urinary proteins as possible non-invasive biomarkers with
potential value in the differential diagnosis of MCD and FSGS. These biomarkers would reduce the number of
misdiagnoses, avoiding unnecessary or inadequate treatments.
Keywords: Focal segmental glomerulosclerosis, Glomerular disease, Mass spectrometry, Minimal change disease,
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Background
Minimal change disease (MCD) and primary focal seg-
mental glomerulosclerosis (FSGS) are glomerular dis-
eases defined by lesions of the podocyte. These diseases
are main causes of idiopathic nephrotic syndrome in
children and adults and are characterized by proteinuria,
hypoalbuminemia, hyperlipidemia and edema, without
an underlying etiology [1, 2]. The final diagnosis of
glomerular diseases is based on renal biopsy findings
and their correlation with clinical, laboratory and sero-
logical results. Moreover, renal biopsy is useful for deter-
mining the prognosis and for choosing the most
appropriate treatment, although the invasiveness of this
technique may lead to serious complications [3–5].
Anatomopathologic study combines conventional light
microscopy, immunohistology and electron microscopy,
and requires an adequate amount of tissue, with a suffi-
cient number of glomeruli to evidence the lesion [6–8].
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Light microscopy shows normal glomeruli in MCD
and segmental scarring in some, but not all, glomeruli in
FSGS. In both entities, electron microscopy typically
demonstrates specific ultrastructural findings of diffuse
effacement of podocytes’ foot processes in the absence
of electron-dense deposits [9, 10]. Due to the focal na-
ture of FSGS, it is complicated to identify this lesion if
no affected glomeruli are sampled in the biopsy, and a
misdiagnosis of these patients as MCD may occur [8].
The correct diagnosis is crucial to an effective treatment,
as MCD is typically responsive to steroid therapy with
excellent long-term prognosis, whereas FSGS is usually
resistant to steroid therapy and has progressive glomerular
filtration rate loss [11, 12]. Consequently, the different
therapy approach and the toxicity of steroids make it espe-
cially important to differentiate between these disorders.
During the last decades, major technological advances
in the field of proteomics have greatly encouraged the
search for diagnostic biomarkers of diseases in biological
fluids, because extracellular proteins provide valuable
information on the physiological state of the entire
organism and of specific organs. For this purpose, two-
dimensional gel electrophoresis coupled with mass spec-
trometry (MS) is a commonly used approach. Recently,
two-dimensional differential gel electrophoresis (2D-
DIGE) has emerged, in which various protein sources
are fluorescently labeled, mixed, and run simultaneously
on the same polyacrylamide gel. This methodology allow
the separation and quantitative analysis of two or more
different protein samples within the same gel, reducing gel
to gel variation and overcoming the reproducibility and
sensitivity limitations of the traditional two-dimensional
gel electrophoresis [13].
Among the different biological fluids, urine has the
advantage of being obtained easily and non-invasively, in
large amounts, and at minimum cost. In addition, urine
contains proteins from plasma and from the kidneys,
reflecting both systemic and renal physiology. Several
studies have been conducted to identify urinary bio-
markers of kidney diseases [14–18].
In this study, the urinary proteome of a group of MCD
and FSGS biopsy-diagnosed patients was compared
aiming to find out candidate biomarkers capable to
differentiate between these glomerular diseases.
Methods
Patients
In the period between January 2007 and December
2013, 49 patients biopsy-diagnosed of MCD (n = 24) and
primary FSGS (n = 25) were included in this prospective
study. Inclusion criteria were: i) Caucasian race, ii) >18 years
old, iii) diagnosis achieved by renal biopsy during the initial
nephrotic syndrome presentation and before starting any
pharmacological therapy (steroids, immunosuppressant
drugs, angiotensin converting enzyme inhibitors, angio-
tensin receptor blockers, etc.), iv) stable renal function
(follow-up two years after diagnosis). Clinical or patho-
logical features indicating a secondary cause such as
autoimmune diseases, infections, cancer or exposure to
nephrotoxic drugs were excluded.
Urine and blood samples were collected the same day
of renal biopsy, prior to performing it. All samples were
processed identically.
The Research Ethics Committee of the Germans Trias i
Pujol Hospital approved the study protocol and all patients
gave their written informed consent to participate.
Study design
MCD and FSGS patients were randomly subdivided into
a training set (10 MCD, 11 FSGS) used to perform the
2D-DIGE analysis, and a validation set (14 MCD, 14
FSGS) used to validate the results.
Renal biopsy
Patients’ histological diagnosis was achieved by a
percutaneous renal biopsy.
Biopsies were performed using a Bard Monopty
Disposable Core Biopsy Instrument (Bard Biopsy
Systems, Tempe, AZ, USA) under ultrasound guid-
ance and routinely processed for light microscopy,
immunofluorescence, and electron microscopy exam-
ination according to established protocols and image
analysis techniques. Light microscopy sections were
stained hematoxylin and eosin, periodic acid Schiff,
silver methenamine, Masson’s trichrome and Congo red.
Immunofluorescence was performed by incubating cryo-
stat sections with polyclonal fluorescein isothiocyanate-
conjugated secondary antibodies against IgG, IgM, IgA,
C3, C1q, C4, kappa, lambda and fibrinogen (Dako,
Glostrup, Denmark). Tissue samples for electron micros-
copy were processed according to established techniques.
Briefly, samples were fixed in 2% glutaraldehyde in phos-
phate buffer, post-fixed in 1% osmium tetroxide and
embedded in epon epoxy resin. Ultrathin sections were
stained with uranyl acetate and lead citrate.
Anthropometric and biochemical parameters
Body surface area was calculated according to Dubois
method [19]. Serum creatinine levels were determined
using a modified Jaffe kinetic reaction (Roche Diagnostics,
Basel, Switzerland). All patients underwent a complete
haematological study that included serum glucose
(hexokinase method) and serum protein (biuret
method). Twenty-four hour proteinuria was measured
spectrophotometrically on a Cobas u711 analyzer
(Roche Diagnostics) according to the manufacturer’s
instructions.
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Urine collection
A first morning void was collected from all patients into
a sterile plastic tube and immediately centrifuged at
2,100 g for 30 min at 4 °C to remove cell debris and
particulate matter. The supernatant was recovered,
adjusted to neutral pH with 1 M NH4HCO3, aliquoted,
and immediately frozen at −80 °C until further analysis.
Sample labeling and two-dimensional gel electrophoresis
The subset of samples from the training set were pooled to-
gether (10 MCD in sample #1 and 11 FSGS in sample #2),
adding an equal amount of protein from each patient
(500 μg). Total protein concentration was assessed with
the Quick Start Bradford protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA) according to manu-
facturer instructions.
Pooled samples were centrifuged at 10,000 g for
10 min and the supernatant was precipitated by 2DE-
CleanUp (GE Helthcare Life Science, Piscataway, NJ,
USA). The pellets were resuspended in 100 μl of lysis
buffer (8 M Urea, 2.5% CHAPS, 2% ASB-14 and 30 mM
Tris–HCl, pH 8.5).
To compare the urine proteomes of both glomerular
entities, 75 μg of sample #1 and 75 μg of sample #2 were
labeled with different CyDye fluorofors (Cy2 for a pool
of both samples, Cy3 for sample #1 and Cy5 for sample
#2) before the two-dimensional polyacrylamide gel elec-
trophoresis (2D-PAGE). Each sample was labeled with 8
pmol of CyDye per μg of protein and incubated on ice
for 30 min in the dark. The labelling reaction was
quenched by adding 1 μl of 10 mM lysine and incubated
on ice for 10 min in the dark, according to manufac-
turer’s instructions (GE Healthcare Life Science).
2D-PAGE with immobilized pH gradient was carried
out according to Görg et al. [20]. The labelled samples
#1 and #2 were mixed together and then run in the first-
dimension by isoelectric focusing (IEF), using the cup-
loading method, onto previously rehydrated 24 cm IPG
drystrips (GE Healthcare Life Science) with immobilized
linear 3–10 pH gradient. IEF was performed at 300 V for
1 h, followed by 3 gradient steps (1000 V for 30 min,
5000 V for 80 min, and 8000 V for 30 min) and finally
8000 V for 2 h. On completion of the IEF, the strips were
equilibrated and proteins separated on the second-
dimension on a 12% polyacrylamide gel. The electro-
phoresis was performed at 14 °C until the front of fast
migrating ions reached the bottom of the gel. The ana-
lytical gels were run in triplicate.
Fluorescence images of the gels were acquired on a
Typhoon 9400 scanner (GE Healthcare Life Science)
at appropriate wavelengths for Cy3 and Cy5 dyes, and
at a resolution of 100 μm. Digitalized images were
evaluated using SameSpots v4.0 software (TotalLab
Ltd., Newcastle, UK).
Spot picking and mass spectrometric protein
identification
Preparatory 2D-PAGE gels were run to be visualized by
colloidal Coomassie staining. Stained gels were scanned
with Typhoon scanner and resulting images were
matched and aligned with the previous Cy3 and Cy5
fluorescence images. Those spots whose protein abun-
dance was increased or decreased more than 1.5-fold
were listed for being identified by matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF)
peptide mass fingerprinting. The spots of interest were
excised from the polyacrylamide gel, destained, and
digested with 30 ng of sequencing grade trypsin (Promega,
Madison, WI, USA) for 4 h at 37 °C. Peptides were eluted
by centrifugation with 40 μl of acetonitrile:H2O (1:1) and
0.2% trifluoroacetic acid.
For MS analysis, the samples were prepared by mixing
0.5 μl of sample with the same volume of a solution of
alpha-cyano-4-hydroxycinnamic acid matrix (10 mg/ml
Table 1 Demographic and clinical characteristics of the study population
Training Set Validation Set PT-V
MCD FSGS P MCD FSGS P MCD FSGS
No. of subjects 10 11 14 14
Age (years) 39.5 (28.0 –68.0) 57.0 (31.0 –71.0) 0.57 55.5 (30.0 –72.0) 54.5 (36.0 –59.0) 0.45 0.32 0.85
Female/male ratio 3/7 5/6 0.47 6/8 2/12 0.09 0.52 0.08
Body mass index (kg/m2) 27.3 (21.9 –33.8) 25.5 (24.0 –26.6) 0.68 29.4 (24.2 –30.6) 26.3 (25.1 –28.4) 0.63 0.76 0.41
Body surface area 1.7 (1.7 –1. 9) 1.8 (1.6 –1.8) 0.83 1.8 (1.6 –1.9) 1.9 (1.8 –2.0) 0.35 0.52 0.11
Serum glucose (mg/dl) 91 (81–101) 88 (83–97) 0.89 84 (81–94) 94 (87–97) 0.19 0.44 0.67
Serum protein (g/dl) 4.4 (3.7 –4.7) 5.0 (4.1 –6.2) 0.09 4.7 (4.1 –4.9) 6.1 (4.5 –6.3) 0.05 0.29 0.56
Serum creatinine (mg/dl) 0.9 (0.8 –1.0) 1.2 (0.9 –1.2) 0.12 0.9 (0.8 –1.3) 1.3 (0.9 –1.8) 0.24 0.64 0.62
Proteinuria (g/24 h) 10.6 (2.3 –12.2) 3.5 (2.5 –7.4) 0.29 9.7 (5.9 –15.0) 3.4 (1.7 –4.5) 0.004 0.52 0.64
Data are shown as median (interquartile range)
Differences between groups were tested using the non-parametric Kruskall Wallis test. PT-V shows P value between training and validation set. P < 0.05 was
considered significant
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in 30% acetonitrile, 60% water, and 0.1% trifluoroacetic
acid) and were spotted onto a ground steel plate (Bruker
Daltonics, Bremen, Germany) and allowed to air-dry. MS
spectra were recorded in the positive ion mode on an ultra-
fleXtreme time-of-flight instrument (Bruker Daltonics). Ion
acceleration was set to 25 kV. All mass spectra were
externally calibrated using a standard peptide mixture
(Bruker Daltonics).
Protein identifications were carried out by Mascot
search engine (Matrix Science, Boston, MA, USA),
against the NCBInr protein database with the following
parameters: 3 maximum missed trypsin cleavages, cyst-
eine carbamidomethylation and methionine oxidation as
variable modifications and 50 ppm tolerance.
Enzyme-linked Immunosorbent assay (ELISA)
The concentration of the proteins identified was assessed
using commercially available ELISA kits (Additional file 1)
according to manufacturer’s instructions. Each sample
was assayed in duplicate. Absorbance optical density
values were read fluorometrically at 450 nm on a
Varioskan Flash spectral scanning reader (Thermo
Table 2 List of proteins identified in urine from training set using peptide mass fingerprinting
# Spota P-value MCD FSGS Foldb Trendc Protein name Gene name UniProt
accession no.d




1,064 0.004 0.39 1.67 4.3 Down Branched-chain-amino-acid
aminotransferase, mithocondrial
BCAT2 O15382 19.9 5 42.4
1,070 0.004 0.18 2.04 11.5 Down Nuclear inhibitor of protein
phosphatase I
PPP1R8 Q12972 28.2 7 48.4
1,334 <0.001 1.79 0.44 4.1 Up Alpha-1-antitrypsin SERPINA1 P01009 21.3 6 44.6
Platelet-activating factor receptor PTAFR P25105 17.3 5 46.5
Cyclin-Y CCNY Q8ND76 32.6 7 49.8
1,352 <0.001 1.79 0.43 4.2 Up Alpha-1-antitrypsin SERPINA1 P01009 49.3 13 51.7
1,354 <0.001 1.77 0.40 4.5 Up Alpha-1-antitrypsin SERPINA1 P01009 49.3 18 86.3
Transmembrane channel-like
protein 1
TMC1 Q8TDI8 23.9 15 33.4
1,356 <0.001 1.85 0.38 4.8 Up Transcription elongation factor 1
homolog
ELOF1 P60002 51.8 7 36.2
1,363 <0.001 1.51 0.59 2.6 Up Transferrin TF P02787 24.5 12 64.9
1,392 0.01 0.31 1.57 5.1 Down Serum albumin ALB P02768 28.1 16 58.6
Leucine-rich repeat-containing
protein C10orf11
c10orf11 Q9H2I8 36.9 6 41.6
1,400 0.005 2.18 0.38 5.7 Up Serum albumin ALB P02768 39.4 21 85.1
1,408 0.006 2.17 0.49 4.4 Up Serum albumin ALB P02768 53.2 31 92.1
1,458 0.002 0.28 1.69 6.1 Down PEST proteolytic signal-containing
nuclear protein
PCNP Q8WW12 51.7 5 38.6
Branched-chain -amino-acid
aminotransferase, mithocondrial
BCAT2 O15382 19.9 5 42.4
1,460 <0.001 0.25 1.72 7 Down Leucine-rich repeat-containing
protein C10orf11
c10orf11 Q9H2I8 36 9 32.7
Calretinin CALB2 P22676 32.1 7 27.9
1,468 <0.001 2.22 0.71 3.1 Up Serum albumin ALB P02768 24.8 21 80.2
39S Ribosomal protein L17,
mithocondrial
MRPL17 Q9NRX2 62.9 9 40
Humanin-like protein 6 HN6 P0CJ73 100 7 64.1
1,469 <0.001 2.98 0.68 4.4 Up Serum albumin ALB P02768 28.2 25 56.6
Histatin-3 HTN3 P15516 68.6 4 36.7
7,740 <0.001 1.27 0.49 2.6 Up Zinc-alpha-2-glycoprotein AZGP1 P25311 155
7,810 <0.001 1.27 0.49 2.6 Up Zinc-alpha-2-glycoprotein AZGP1 P25311 28.9 10 61.9
aSpot number generated by SameSpots image analysis software, referencing the spots shown on Additional file 2
bRatio of protein expression between MCD and FSGS
cUp: up-regulated in MCD compared to FSGS; Down: down-regulated in MCD compared to FSGS
dAccession number from NCBInr database
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Fisher Scientific, Vantaa, Finland). The measured
concentrations were assessed with the SkanIt Software
for Varioskan Flash (version 2.4.1) by extrapolation
from a standard curve generated from the standards
supplied in the kits.
Statistical analyses
The first step was performed using univariate and bivari-
ate analyses. For continuous variables, expressed as me-
dian (interquartile range), groups were compared using
the non-parametric Kruskal-Wallis test. For categorical
variables, differences among groups were tested using
Likelihood Ratio Chi-Square statistic.
A decision tree [21] was performed to obtain the set of
the most discriminative proteins between MCD and FSGS
patients. Ten 5-fold cross-validations were performed
aiming to validate the decision tree. In addition, for the
validation of the decision tree analysis, the corresponding
area under the ROC curve (AUC) was calculated.
Statistical analyses were performed with the SAS
software v9.3 (SAS Institute Inc., Cary, NC, USA).
Significance level was fixed at 0.05.
Results
Demographical and clinical data of patients are presented
in Table 1.
Renal biopsies contained 22.36 ± 11.50 glomeruli.
2D-DIGE MS
A total of 394 matched protein spots were detected in
2D-DIGE images (Additional file 2). A total of 242 spots
showed a differential abundance when comparing MCD
and FSGS (ANOVA, P < 0.05); 57.4% and 42.6% were
up-regulated in MCD and FSGS, respectively.
Differentially abundant protein spots (with average-
fold change > 2 and P < 0.01) were targeted for MS
analysis. The protein identification gave a total of 25
confident identifications, representing 16 proteins.
Eleven of these proteins were up-regulated in MCD
patients and 5 were up-regulated in FSGS patients.
Table 2 shows the list of the identified proteins; in cases
where multiple identifications were made from the same
spot, all proteins are reported.
Validation by ELISA
The results of the validation are shown on Table 3
and Fig. 1.
Three DIGE spots, up-regulated in MCD, were identified
as alpha-1-antitrypsin (AAT). The concentration of this
protein was significantly higher in the urine of MCD
patients.
The identification of the DIGE spot #1,334 resulted in
2 proteins, platelet-activating factor receptor (PTAFR)
and cyclin-Y, in addition to AAT. By ELISA we found
the presence of these proteins in the urine of some
patients of the validation set, but no differences were
observed when comparing MCD and FSGS.
One DIGE, up-regulated in MCD, was identified as
transferrin (TF). By ELISA, we found a higher concen-
tration of this protein in the urine of MCD.
Another spot up-regulated in MCD was identified as
Histatin-3 (HTN). This protein was only detected by
ELISA in 8 patients, with higher concentration in those
diagnosed MCD.
Another spot up-regulated in MCD was identified as
39S ribosomal protein L17, mitochondrial (MRPL17).
The concentration of this protein was higher in the
urine of MCD patients.
One DIGE up-regulated in FSGS was identified as
calretinin (CALB2). This protein was in a higher concen-
tration in urine of FSGS patients.
The spot #1,458, up-regulated in MCD patients, was
identified as PEST proteolytic signal-containing nuclear
protein. By ELISA, no differences were found.
The rest of proteins identified were not detected by
ELISA in the urine of patients from the validation set.
Decision tree analysis
In the first step for building the decision tree, CALB2
was used for classifying patients. Hence, 2 groups were
obtained: 19 patients (14 MCD, 5 FSGS) with levels of
CALB2 < 6.4 ng/ml and 9 patients (9 FSGS) with levels
of CALB2 > = 6.4 ng/ml. In the second step, for the
Table 3 Validation results
N Urine concentration P
AAT MCD 13 / 14 193.5 (102.49 –580.0) μg/ml 0.002
FSGS 14 / 14 20.93 (10.45 –101.65) μg/ml
TF MCD 12 / 14 653.63 (241.27 –1,348.38) μg/ml 0.002
FSGS 14 / 14 129.96 (55.41 –267.10) μg/ml
HTN-3 MCD 5 / 14 0.35 (0.32 –0.48) μg/ml 0.03
FSGS 3 / 14 0.22 (0.17 –0.23) μg/ml
MRPL17 MCD 12 / 14 242.98 (174.25 –534.75) pg/ml 0.001
FSGS 14 / 14 111.86 (74.90 –154.78) pg/ml
PCNP MCD 14 / 14 441.67 (152.50 –503.10) pg/ml 0.72
FSGS 12 / 14 348.55 (216.25 –437.70) pg/ml
CALB2 MCD 14 / 14 3.52 (2.88 –4.40) pg/ml 0.002
FSGS 14 / 14 6.98 (4.29 –8.65) pg/ml
CCNY MCD 12 / 14 87.60 (83.40 –91.15) pg/ml 0.71
FSGS 12 / 14 87.70 (84.30 –102.2) pg/ml
PTAFR MCD 5 / 14 0.84 (0.46 –0.98) ng/ml 0.25
FSGS 2 / 14 0.51 (0.36 –0.66) ng/ml
N represents the number of urine samples in which the proteins were
detected by ELISA
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group who had levels of CALB2 < 6.4 ng/ml, the best
partition was using the value of MRPL17 > = 139.29 pg/
ml. To conclude, a final partition was defined by the de-
tection of HTN, in the group who had levels of CALB2
< 6.4 ng/ml and MRPL17 < 139.29 pg/ml.
Accordingly, 4 groups of patients were obtained
(Fig. 2). Group 1 included 9 patients, all of them FSGS
with levels of CALB2 > = 6.4 ng/ml; Group 2 included
11 patients (10 MCD, 1 FSGS) with levels of CALB2 <
6.4 ng/ml and MRPL17 > = 139.29 pg/ml. Moreover,
Fig. 1 Selection of DIGE spots and validation by ELISA
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these patients showed high levels of AAT, TF, HTN
and PTAFR; Group 3 included 2 FSGS patients with
levels of CALB2 < 6.4 ng/ml, levels of MRPL17 <
139.29 pg/ml and detection of HTN; Group 4 included
6 patients (4 MCD, 2 FSGS) with levels of CALB2 <
6.4 ng/ml, levels of MRPL17 < 139.29 pg/ml and no
detection of HTN. Groups 2 and 4 were mainly com-
posed of MCD patients, and Groups 1 and 3 included
only FSGS patients. Therefore, the predicted-MCD
patients were those in Groups 2 and 4, and the
predicted-FSGS patients were those in Groups 1 and
3. All MCD patients were classified as predicted-
MCD, while 78.6% of FSGS were correctly predicted.
From the validation analysis, the AUC was 0.89 and
95% Confidence Interval = [0.78, 1].
Discussion
We included a highly selected group of patients with
clinical and histological diagnosis of MCD and FSGS.
The diagnosis of FSGS is established by the finding of at
least a single abnormal glomerulus and it has been
stated that the probability of misdiagnosis is statistically
relevant when fewer than eight glomeruli are found in
biopsy samples [8]. In our study, all tissue samples
contained more than eight glomeruli. Moreover, we can
state that all patients were correctly classified, as those
diagnosed MCD achieved a complete remission, without
any relapse for at least two years.
In recent years, several research groups have proposed
different urinary biomarkers to differentiate between these
glomerular diseases, such as CD80 and TGFβ [22, 23], but
there is not enough evidence to use them in clinical prac-
tice. These candidate biomarkers need further validation
and in a larger cohort.
Of our results, we consider highly interesting the find-
ing of a set of proteins whose concentration in urine
was different between these glomerular diseases. With
some of these proteins, named calretinin, histatin-3 and
39S ribosomal protein L17, we built a decision tree
capable to predict patient’s pathology.
These results were obtained after conducting a prote-
omic study. Beside direct analysis of renal tissue, urin-
ary proteome study has potential value in the none-
invasive diagnosis of kidney diseases diagnosis. We
focused on MCD and FSGS in which the histological
study may be similar and lead to an erroneous diag-
nosis. Consequently, our results may be useful to cli-
nicians to confirm the diagnosis and thereby avoid
unnecessary or inadequate treatments.
The comparison of the urinary proteome of MCD and
FSGS patients was achieved by 2D-DIGE, resulting in 16
proteins as possible biomarkers. Various proteins were
identified in different spots, and numerous spots con-
tained more than one protein, making it difficult to attri-
bute abundance changes to a specific protein. For that
reason, the results obtained by 2D-DIGE were validated
by independent ELISA analyses.
Various DIGE spots that were up-regulated in MCD were
identified as AAT. By ELISA we corroborated that this pro-
tein was in a higher concentration in the urine of MCD
patients. AAT is a 52-kDa glycoprotein and the most abun-
dant circulating serine protease inhibitor of a broad range of
proteases, mainly against neutrophil elastase. AAT protects
tissues from enzymes released from cells when they are
injured and inflamed. Other functions of AAT have been
suggested, such as modulating immunity, inflammation and
apoptosis [24, 25]. AAT is mainly synthesized in the liver
and to a lesser extent by a variety of extra-hepatic tissues,
such as renal tubular epithelial cells. Several studies have
revealed that AAT protects the kidney by anti-apoptotic
and anti-inflammatory routes in renal ischemic/reperfusion
injury and it has been proposed as a biomarker for acute
kidney injury (AKI) [26–28]. Since AKI can be due to a
glomerular injury, we paid attention at the renal function of
our patients and observed that there were no differences in
serum creatinine levels between MCD and FSGS.
Fig. 2 Decision tree analysis
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Other studies have described a high presence of
AAT in the urine of patients with nephrotic syn-
drome, and a practical absence in the urine of healthy
subjects [29, 30]. In agreement, in a previous study,
by analyzing the urinary peptidome, we found one
peptide, identified as AAT, that showed a higher in-
tensity in MCD compared with FSGS [31].
The present study also revealed higher levels of TF in
MCD. Urinary TF results from abnormal permeability of
the glomerular basement membrane, and it has been
suggested to be a marker for early stages of glomerular
diseases. Increased urinary TF excretion has been sug-
gested to precede the development of microalbuminuria
in glomerular diseases [32]. Other studies have found
that urinary TF may predict the severity of mesangial
cellularity and glomerulosclerosis in the early stages of
glomerular diseases [33].
MRPL17 is a protein encoded by nuclear genes and
helps in protein synthesis within the mitochondrion. To
our knowledge, there are no studies relating this protein
with kidney diseases.
We identified CALB2 as another possible candidate
biomarker capable of differentiating MCD from FSGS.
CALB2, a 29 kDa calcium-binding protein belonging
to the troponin C superfamily, is predominantly
expressed in specific neurons of the central and
peripheral nervous system. This protein is involved in
diverse cellular functions including intracellular calcium
buffering, messenger targeting, and the modulation of
neuronal excitability. CALB2 has been proposed as a
diagnostic marker for some human diseases, including
Hirschsprung disease and some cancers, such as
mesothelioma and lung tumours [34–36].
Conclusions
In conclusion, given the difficulty in differentiating, in
some cases, between MCD and FSGS by evaluation of
renal biopsies, it becomes necessary to search for diag-
nostic biomarkers. In this study, we built a decision tree
which seems a good tool for predicting patient’s path-
ology when there are doubts if it is MCD or FSGS,
although future efforts must be made to include more
patients and to evaluate its effectiveness.
Additional files
Additional file 1: (Table) List of commercially available ELISA kits used
to validate proteins identified by peptide mass fingerprinting. (PDF 7 kb)
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